The Skin Cancer Foundation Journal

MAY 2015

The 2012 edition of The Skin Cancer Foundation Journal features medically reviewed, reader-friendly articles such as tanning, the increasing incidence of skin cancer diagnoses among young women, & the prevalence of melanoma among white males over 50.

Issue link: https://skincancer.epubxp.com/i/526209

Contents of this Issue

Navigation

Page 108 of 115

1 0 7 For the latest information and updates go to: SkinCancer.org 7. Roth AJ. FDA accepts sBLA for adjuvant ipilimumab in melanoma. OncLive March 2, 2015. http://www. onclive.com/web-exclusives/FDA-Accepts-sBLA-for- Adjuvant-Ipilimumab-in-Melanoma PERFECTING THE TARGETED THERAPIES (P.79) 1. Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell 2012; 150(2):2 51-63. 2. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363(9):809-19. 3. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366(8):707-14. 4. Chapman PB, Hauschild A, Robert C. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New Engl J Med 2011; 364(26):2507-2516. 5. McArthur GA, Chapman PB, Robert C, et al. Im- proved survival with vemurafenib in BRAFV600E and BRAFV600K mutation–positive melanoma. Lancet Oncol 2014. (in press). 6. Luke JJ, Hodi FS. Ipilimumab, vemurafenib, dab- rafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant mela- noma. Oncologist 2013; 18:717-25. 7. FDA grants Genentech's cobimetinib priority review for use in combination with Zelboraf (vemurafenib) in advanced melanoma. Genentech news release, Febru- ary 18, 2015. 8. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination vemurafenib and ipili- mumab. N Engl J Med 2013; 368:1365-6. THE SUN KEEPS RISING (P.80) 1. Hayutin A, Beals M, Borges E. The aging US work- force. A chartbook of demographic shifts. Introduction. Stanford Center on Longevity 2013. http://longevity3 .stanford.edu/wp-content/uploads/2013/09/The_ Aging_U.S.-Workforce.pdf. Accessed March 12, 2015. 2. Sun Protection. Cancer Trends Progress Report – 2009/2010 Update. National Cancer Institute. http:// progressreport.cancer.gov/doc_detail.asp?pid=1&did =2007&chid=71&coid=711&mid. Accessed Novem- ber 1, 2010. 3. National Cancer Institute. A snapshot of mela- noma. http://www.cancer.gov/aboutnci/servingpeople/ snapshots/melanoma.pdf. updated Oct 2011; accessed Aug 27, 2012. 4. Syrigos KN, Tzannou I, Katirtzoglou N, Georgiou E. Skin cancer in the elderly. In Vivo 2005; 19(3):643-52. 5. Pfahlberg A, Kolmel KF, Gefeller O. Timing of exces- sive ultraviolet radiation and melanoma: epidemiology does not support the existence of a critical period of high susceptibility to solar ultraviolet radiation-induced mela- noma. Brit J Dermatol March 2001; 144:3:471. 6. Merimsky O, Inbar M. Cigarette smoking and skin cancer. Clin Dermatol 1998;16(5):585-8. 7. Boyd AS, Stasko T, Lloyd E, et al. Cigarette smok- ing–associated elastotic changes in the skin. J Am Acad Dermatol 1999; 41:23-6. 8. Norman R. 100 Questions & Answers about Aging Skin. Jones and Bartlett Publishers LLC 2010; Sudbury, MA. 9. Godar DE, Urbach F, Gasparro FP, Van der Leun JC. UV doses of young adults. Photochem Photobiol 2003; 77(4):453-457. 10. Norman R. Preventive Dermatology. London, UK: Springer; 2010. 11. Wehner M, Chren M-M, Nameth D, et al. Interna- tional prevalence of indoor tanning: a systematic review and meta-analysis. JAMA Dermatol 2014; 150(4):390- 400. Doi: 10.1001/jamadermatol.2013.6896. WHAT IS MY MELANOMA RISK? (P.83) 1. Robins P, Perez M. Understanding Melanoma, 5th edition, 2015, in press. The Skin Cancer Foundation, New York City. 2. American Cancer Society. Cancer Facts & Figures 2015. http://www.cancer.org/acs/groups/content/@editorial/ documents/document/acspc-044552.pdf. Accessed January 9, 2015. 3. Lo JA, Fisher DE. The melanoma revolution: from UV carcinogenesis to a new era in therapeutics. Science 2014; 346(6212):945-9. 4. Penn LA, Qian M, Zhang E, et al. Development of a melanoma risk prediction model incorporating MC1R genotype and indoor tanning exposure: impact of mole phenotype on model performance. PLoS One 2014; 9(7):e101507. 5. Even Normal Moles Mean Risk. The Skin Cancer Foundation website. www.SkinCancer.org/publications/ sun-and-skin-news/late-fall-2014-31-3/moles . Checked April 17, 2015. 6. Parkin DM, Mesher D, Sasieni P. Cancers attribut- able to solar (ultraviolet) radiation exposure in the UK in 2010. Br J Cancer 2011; 105:S66-S69. 7. Chang YM, Barrett JH, Bishop DT, et al. Sun expo- sure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls. Int J Epide- miol 2009; 38(3):814-30. 8. Wu S, Han J, Laden F, Qureshi AA. Long-term ultravi- olet fux, other potential risk factors, and skin cancer risk: a cohort study. Cancer Epidemiol Biomar Prev; 2014. 23(6); 1080-1089. 9. Wehner M, Chren M-M, Nameth D, et al. Interna- tional prevalence of indoor tanning: a systematic review and meta-analysis. JAMA Dermatol 2014; 150(4):390- 400. Doi: 10.1001/jamadermatol.2013.6896. 10. Ogden N. General and Plastic Surgery Devices: Re- classifcation of Ultraviolet Lamps for Tanning, Henceforth To Be Known as Sunlamp Products and Ultraviolet Lamps Intended for Use in Sunlamp Products.https://www. federalregister.gov/articles/2014/06/02/2014-12546/ general-and-plastic-surgery-devices-reclassifcation-of- ultraviolet-lamps-for-tanning-henceforth-to. Accessed June 9, 2014. 11. Bradford PT, Freedman DM, Goldstein AM, Tucker MA. Increased risk of secondary primary cancers af- ter a diagnosis of melanoma. Arch Dermatol 2010; 146(3):265-272. 12. Jensen P, Hansen S, Moller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999; 40 (2 Pt 1):177-86. WHAT IS MY MELANOMA RISK? (TABLE 1) 1. Williams PF, Olsen CM, Hayward NK, et al. Melano- cortin 1 receptor and risk of cutaneous melanoma: a meta-analysis and estimates of population burden. Int J Cancer 2011; 129(7):1730-40. 2. Mayer JE, Swetter SM, Fu T, Geller AC. Screening, early detection, education, and trends for melanoma: current status (2007-2013) and future directions: Part I. Epidemiology, high-risk groups, clinical strategies, and diagnostic technology. J Am Acad Dermatol 2014; 71(4):611. 3. Penn LA, Qian M, Zhang E, et al. Development of a melanoma risk prediction model incorporating MC1R genotype and indoor tanning exposure: impact of mole phenotype on model performance. PLoS One 2014; 9(7):e101507. SUN UNDONE: REVERSING FACIAL UV DAMAGE (P.20): Deborah S. Sarnoff, MD LIGHT AND DARK (P.25-29): Tim Geaney A FASHION MODEL'S SECRET TO LIFELONG BEAUTY (P.30): Tim Geaney, (P.31): Mark Treitel THE NEW UV: POLLUTION (P.37): [Unilateral Dermatoheliosis] New England Journal of Medicine MY WILD, IRISH SKIN CANCER (P.42): FOX COLLEGE TANNERS: BEFORE AND AFTER TANNING (P. 48-51): Courtney McClanahan; Kirby Williams; Lauren Beloff; Diana Schmitz SUN-ACCESSORIZE YOUR SPORT (P.56-58): Columbia Sportswear; J Crew; Land's End; Specialized; O'Neill; Under Armour; Coolibar; Maui Jim; Christie Brinkley Sunglass Collection; Coppertone Lenses by Vision-Ease CHUCK DEVOE AND A LIFE WELL LIVED (P.60-62): The DeVoe Family ASHLEY'S JOURNEY (P.64-66): The Trenner Family Corbis Images: pg 76, pg 82 [Sun Affected Skin] Getty Images: Cover, pg 36, pg 40 [Carrie Underwood; Lauren Conrad], pg 41 [Seth Meyer], pgs 72-74, pg 88 iStockphoto: pg 9, pg 13, pg 18-19, pg 22, pg 24, pg 33, pg 37 [Cityscape], pg 38, pg 40-41, pg 44-46, pg 51 [Students Using Social Media], pg 52, pg 68-70, pg 77, pg 80-85, pg 108 [Cartagena cityscape; Cartagena waterfront], pg 109 [Edinburgh at night], pg112 Veer: pg 8 [Wooden Nickel; Grooms Suit Jacket Outft] References S K I N C A N C E R F O U N D A T I O N References, Continued Photo Credits

Articles in this issue

Archives of this issue

view archives of The Skin Cancer Foundation Journal - MAY 2015